A carregar...
The use of a new combination of avelumab + axitinib in patients with metastatic kidney cancer in the first line of treatment
Introduction. Simultaneous inhibition of programmed cell death-1 (PD-1)/PD-L1 immune checkpoint and VEGF/VEGFR signaling has a synergistic antitumor effect in preclinical models. This article presents the results of the phase III study JAVELIn Renal 101 (NCT02684006), as well as the experience...
Na minha lista:
Main Authors: | , , |
---|---|
Formato: | Artigo |
Idioma: | Russo |
Publicado em: |
Remedium Group LLC
2021-06-01
|
Colecção: | Медицинский совет |
Assuntos: | |
Acesso em linha: | https://www.med-sovet.pro/jour/article/view/6209 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|